Company Overview of Moderna Therapeutics, Inc.
Moderna Therapeutics, Inc. develops messenger RNA therapeutics. The company provides in vivo drug modality that produces human proteins or antibodies inside patient cells. It also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. The company focuses on disease areas, such as inherited genetic disorders, hemophilic and blood factors, and oncology. Moderna Therapeutics, Inc. has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals, Inc.; and strategic collaborations with Karolinska Institutet, Institut Pasteur, and Karolinska University Hospital. The company was incorporated in 2009 and is based...
200 Tech Square
Cambridge, MA 02139
Founded in 2009
Key Executives for Moderna Therapeutics, Inc.
Founding Chief Executive Officer, President and Director
Co-Founder, Chairman and Member of Technology Advisory Board
President of Research and Development
Senior Vice President of Technology Strategy
Compensation as of Fiscal Year 2015.
Moderna Therapeutics, Inc. Key Developments
Moderna Therapeutics, Inc. Presents at 22nd Annual NewsMakers in the Biotech Industry Investment Conference, Sep-10-2015 10:30 AM
Sep 9 15
Moderna Therapeutics, Inc. Presents at 22nd Annual NewsMakers in the Biotech Industry Investment Conference, Sep-10-2015 10:30 AM. Venue: Millennium Broadway Hotel & Conference Center - Breakout Room 401, 145 West 44th Street, New York, New York, United States.
Moderna Launches Third Venture Company Elpidera for Rare Diseases
May 12 15
Moderna Therapeutics announced the launch of Elpidera LLC, a new Moderna venture focused exclusively on the advancement of mRNA-based medicines for the treatment of rare diseases. Elpidera, which is derived from the Greek word elpida meaning "hope," will leverage Moderna's mRNA platform to create novel therapies to address diseases in small patient populations with severe unmet medical needs. Moderna signed a strategic agreement with Alexion in January 2014 allowing Alexion to have 10 product options in rare diseases. Elpidera will advance programs that are independent from the Alexion programs and proprietary to Moderna, while also supporting Alexion in its efforts to leverage the Moderna technology platform through the existing agreement.
Moderna Therapeutics, Inc. Names Tal Zaks as Chief Medical Officer, Effective March 16, 2015
Mar 16 15
Moderna Therapeutics, Inc. announced that Tal Zaks, M.D., Ph.D., will join Moderna's executive leadership team as chief medical officer, effective March 16. Prior to joining Moderna, Dr. Zaks was senior vice president and head of Global Oncology at Sanofi.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 19, 2014